TUBACEX adapts its Organization to fight COVID-19: Q3 Results

TUBACEX’s sales figure for the first nine months of the year amounts to €389.6 million, which is 18.2% lower than that of the same period last year; while EBITDA stands at €26.4 million, down 42.9%, with a 6.8% margin. These results, determined by the global...

TUBACEX presents its results in a market context dominated by COVID-19

2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.

TUBACEX announces consolidated results and ends 2019 with an EBITDA of €67.1 million

2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.